The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting a strategic portfolio rebalancing by Hong Kong-based investors, Y Intercept Hong Kong Ltd has nearly liquidated its entire position in biotech giant Moderna. According to reports, the firm sold 444,343 shares of Moderna, representing a massive 96.4% decrease in its holdings. Simultaneously, the investment firm reduced its stake in Welltower by 54.6% during the first quarter, leaving its remaining position in the REIT valued at approximately $924,000.
These liquidations occur despite Moderna's recent progress with its RSV vaccine contract and Welltower's robust quarterly earnings driven by the senior housing sector. Per market data, peers such as Pfizer and Ventas have faced similar sectoral headwinds as institutional investors rotate capital away from high-growth stocks that experienced significant volatility in the post-pandemic era.
Regarding market performance, MRNA stood at $68.27 and WELL at $231.59 (at close July 10, 2026). Traders are monitoring these price levels for stability following institutional selling pressure, while also eyeing broader macro catalysts. Recent data from July 6 showed the ISM Services PMI holding at 54, a key indicator that may influence risk appetite across the healthcare and real estate sectors.